TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31278470
Drug: Intracutaneous sterile
Normalized name: Steril-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracutaneous sterile water injection (ISWI)
Study: 26553486
Drug: Liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.8 mg day(-1)
Study: 26553486
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of standard insulin therapy
Study: 23753256
Drug: Regular self-weighing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular self-weighing intervention (two telephone calls, offer of free weighing scales, encouragement to weigh weekly)
Study: 19850640
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose intensity doxorubicin-based regimens
Study: 18226670
Drug: DMPA 150
Normalized name: DMPA
DrugBank: Zytron (DB11768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMPA 150 mg intramuscularly
Study: 11004040
Drug: Bisulfite-containing propofol
Normalized name: Sodium bisulfite
DrugBank: Sodium bisulfite (DB14015)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisulfite-containing propofol 1.5 mg/kg IV
Study: 8823692
Drug: Aceclofenac, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aceclofenac, 100 mg bid orally
Study: 8823692
Drug: Tenoxicam, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam, 20 mg orally at bedtime
Study: 1349496
Drug: Celiprolol 200
Normalized name: celiprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol 200 mg daily for 7 days
Study: 3512461
Drug: Control lotion
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control lotion (vehicle)
Study: 29558782
Drug: Verum (Monapax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verum (Monapax syrup)
Study: 27382456
Drug: Silymarin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (70 mg) administered at three hours and 24 hours after pregnancy termination
Study: 27382456
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered at three hours and 24 hours after pregnancy termination
Study: 24802951
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (500 mg · day(‐1))
Study: 22526068
Drug: Cream containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream containing green tea extract
Study: 9569477
Drug: Recombinant hepatitis
Normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hepatitis B virus (HBV) vaccines administered at 2, 4, and 12 months of age, concurrent with OPV and DTP vaccination.
Study: 9569477
Drug: Whole cell
Normalized name: pertussis, whole cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole cell DTP and three-component acellular DTaPs administered as part of the vaccination schedule.
Study: 9569477
Drug: Antibody response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Antibody response measured by ELISA for HBsAg.
Study: 30661700
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A treatment (100,000 IU intramuscular daily for 7 days)
Study: 30661700
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (blinded placebo daily for 7 days)
Study: 29353426
Drug: Dipyrone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone (1 g) administered preemptively before surgery
Study: 29353426
Drug: Dipyrone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone (1 g) administered in the immediate postoperative period
Study: 27898166
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (7- to 14-day regimen with PPI, clarithromycin, and either amoxicillin or an imidazole)
Study: 27898166
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential therapy (5 days of PPI and amoxicillin followed by 5 days of PPI, clarithromycin, and an imidazole)
Study: 27898166
Drug: 14-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day sequential therapy (5 days of PPI and amoxicillin followed by 5 days of PPI, clarithromycin, and an imidazole)
Study: 24055350
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of Q-HPV vaccine at 0, 6 months (n=259)
Study: 24055350
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of Q-HPV vaccine at 0, 2, 6 months (n=260)
Study: 24055350
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of Q-HPV vaccine at 0, 2, 6 months (n=305)
Study: 24055350
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of Q-HPV vaccine (all subjects)
Study: 18806966
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg SF‐TRE
Study: 18806966
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg SF‐TRE
Study: 18806966
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg SF‐TRE
Study: 16297562
Drug: Current illicit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current illicit drug use (N=253)
Study: 16297562
Drug: Past drug
Normalized name: Paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Past drug use (N=617)
Study: 551921
Drug: Specific hypotensive
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific hypotensive therapy (Ht)
Study: 9230648
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate depot (3.75 mg once a month for 3 months)
Study: 3677283
Drug: Neostigmine, 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine, 0.04 mg.kg‐1
Study: 3677283
Drug: Pyridostigmine, 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine, 0.2 mg.kg‐1
Study: 3677283
Drug: Edrophonium, 0.54
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium, 0.54 mg.kg‐1
Study: 29198157
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol valerate daily plus 4 mg medroxyprogesterone acetate on days 19–30
Study: 29198157
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol valerate daily plus 100 mg micronized progesterone on days 19–30
Study: 27716201
Drug: CRP <
Normalized name: Corticotropin-releasing protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP < 5 mg/L
Study: 18031594
Drug: Oral bisphosphonates
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bisphosphonates (alendronate, risedronate, ibandronate)
Study: 18031594
Drug: Etidronate (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate (administered with an extended between-dose interval)
Study: 18031594
Drug: Non-daily oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-daily oral bisphosphonates
Study: 15731977
Drug: Information group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information group (oral and written information about baby blues and postpartum depression)
Study: 10229740
Drug: Argatroban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban (10 mg/d IV) over 2 hours for 7 days
Study: 9367941
Drug: Drug formulation
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug formulation containing dimethylaminoethanolorotrate (DMAE), vitamins and minerals, 1 capsule per day for 12 weeks
Study: 12620603
Drug: Propranolol (beta-blocker)
Normalized name: beta-Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol (beta-blocker)
Study: 19409854
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone (200 mg)
Study: 9754457
Drug: Neural network
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neural network model for predicting heparin concentrations
Study: 9754457
Drug: NONMEM model
Approvals — FDA: no, EMA: no, PMDA: no
Description: NONMEM model for predicting heparin concentrations
Study: 1882908
Drug: Sucralfate 2
Normalized name: sucralfate 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 2 g, twice daily (b.i.d. group)
Study: 1882908
Drug: Sucralfate 1
Normalized name: sucralfate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 1 g, four times daily (q.i.d. group)
Study: 786314
Drug: Viloxazine (150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine (150-300 mg/day)
Study: 30288563
Drug: Oral isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral isotretinoin (0.5 mg/kg) started on the 31st day after surgery, given every other day for 1 month and then daily for two additional months
Study: 26490434
Drug: Ongoing LMWH
Normalized name: Ongo-Fin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing LMWH treatment for CAT
Study: 26490434
Drug: Cessation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation of LMWH at 6 months' treatment
Study: 24111502
Drug: n‐3 LCPUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 LCPUFA supplementation (fish oil capsules providing 900 mg daily)
Study: 24111502
Drug: Control (matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (matched vegetable oil capsules without n‐3 LCPUFA)
Study: 24111502
Drug: n‐3 LCPUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 LCPUFA supplementation (fish oil capsules)
Study: 24111502
Drug: Control (matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (matched vegetable oil capsules)
Study: 18786624
Drug: UDB 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDB 0.06 mg
Study: 18786624
Drug: UDB 0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDB 0.12 mg
Study: 18786624
Drug: UDB 0.24
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDB 0.24 mg
Study: 18786624
Drug: Commercial budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Commercial budesonide 0.25 mg
Study: 15791100
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (100 mg/kg before incision and 10 mg/kg/h during surgery)
Study: 11809113
Drug: Octreotide (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (0.1 mg IV injection + continuous drip at 25 microg/h for 24 hours)
Study: 11809113
Drug: Octreotide (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (0.1 mg IV injection + continuous drip at 42 microg/h for 24 hours)
Study: 11809113
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg IV injection + continuous drip at 8 mg/h for 24 hours)
Study: 11809113
Drug: Octreotide (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (same dosage as in group 1 for 72 hours)
Study: 11809113
Drug: Omeprazole (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (same dosage as in group 3 for 72 hours)
Study: 2896866
Drug: Intravenous desferrioxamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous desferrioxamine 1 g at the end of each dialysis for six months
Study: 28814805
Drug: Intercalating gefitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intercalating gefitinib (250 mg/day on days 15-25 of each cycle until disease progression)
Study: 28814805
Drug: Chemotherapy (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (gemcitabine 1250 mg/m2 plus carboplatin 5 AUC)
Study: 26091193
Drug: Asenapine 2.5
Normalized name: asenapine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine 2.5 mg b.i.d.
Study: 26091193
Drug: Asenapine 5
Normalized name: asenapine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine 5 mg b.i.d.
Study: 26598478
Drug: Asenapine 10
Normalized name: asenapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine 10 mg b.i.d.
Study: 26598478
Drug: Asenapine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine (all doses)
Study: 23578031
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol (FF/VI) 200/25 μg
Study: 23578031
Drug: Prednisolone 10
Normalized name: prednisolone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 10 mg daily
Study: 19692802
Drug: Peroperatively applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peroperatively applied local doses of a mix containing corticosteroids
Study: 19692802
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (steroid and control)
Study: 16987866
Drug: Lamivudine monotherapy
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine monotherapy (100 mg per day for 48 weeks)
Study: 16987866
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment with lamivudine (100 mg per day for 20 weeks) followed by interferon‐alpha‐2b (5 million units three times per week for 4 weeks, then 5 million units three times per week for another 24 weeks)
Study: 10927061
Drug: Modified hysterosalpingography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified hysterosalpingography (1-2 mL of water-soluble contrast medium followed by 10 mL of saline)
Study: 8829934
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia (TIVA) with a propofol and alfentanil mixture
Study: 2003707
Drug: Single cycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single cycle of perioperative chemotherapy (cyclophosphamide, methotrexate, fluorouracil, leucovorin)
Study: 2003707
Drug: Six cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six cycles of conventionally timed chemotherapy (cyclophosphamide, methotrexate, fluorouracil, prednisone) for premenopausal women or this combination plus tamoxifen for postmenopausal women
Study: 2003707
Drug: Both perioperative
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both perioperative and conventionally timed chemotherapy for a 7-month course of adjuvant therapy
Study: 27388365
Drug: Moderately unhealthy
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately unhealthy oral conditions based on OHAT scores
Study: 27388365
Drug: Unhealthy oral
Normalized name: Healthy Mama Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unhealthy oral conditions based on OHAT scores
Study: 27388365
Drug: Moderate-to-very poor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-to-very poor oral hygiene assessed by PI
Study: 27388365
Drug: Overall oral
Normalized name: Feverall Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall oral health status
Study: 25961461
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg anacetrapib with background treatment of placebo
Study: 25961461
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg anacetrapib with background treatment of 20 mg atorvastatin
Study: 16001165
Drug: Oral vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vinorelbine 70 mg/m2
Study: 16001165
Drug: Intravenous vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vinorelbine 30 mg/m2
Study: 12581972
Drug: 2.0 mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg/ml ropivacaine (group R)
Study: 12581972
Drug: 1.25 mg/ml
Normalized name: menthol 1.25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg/ml ropivacaine plus 1.0 microg/ml fentanyl (group RF1)
Study: 12581972
Drug: 1.0 mg/ml
Normalized name: P.T.E.-4, 1 mcg-0.1 mg-0.025 mg-1.0 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/ml ropivacaine plus 2.0 microg/ml fentanyl (group RF2)
Study: 12581972
Drug: 1.0 mg/ml
Normalized name: P.T.E.-4, 1 mcg-0.1 mg-0.025 mg-1.0 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/ml ropivacaine plus 4.0 microg/ml fentanyl (group RF4)
Study: 7776420
Drug: Rufloxacin 200
Normalized name: ofloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rufloxacin 200 mg once daily (after a loading dose of 400 mg on day 1)
Study: 25312446
Drug: Add-on therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on therapy
Study: 26522053
Drug: Combination DOX/mCTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination DOX/mCTX
Study: 26522053
Drug: Single-agent DOX
Normalized name: MTC-DOX
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-agent DOX
Study: 17584355
Drug: Nurse's education
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse's education using short message service (SMS) for 12 weeks, including diet, exercise, medication adjustment, and self-monitoring of blood glucose levels.
Study: 15189746
Drug: Meropenem 125
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem 125 mg/h
Study: 15189746
Drug: Meropenem 250
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem 250 mg/h
Study: 15189746
Drug: Meropenem 125
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem 125 mg/h and 250 mg/h
Study: 15189746
Drug: Meropenem continuous
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem continuous infusion
Study: 9605374
Drug: MNS technique
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: MNS technique (4 injections of 10 mL each)
Study: 9605374
Drug: TA technique
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA technique (2 injections of 20 mL each)
Study: 2258780
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment phases
Study: 7374099
Drug: Isotonic electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic electrolyte solution (control)
Study: 30551540
Drug: Topical emulgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical emulgel formulation with Mimosa pudica seed extract
Study: 20950166
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 μg daily injections)
Study: 1958279
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (low-dose cyclosporin, azathioprine, methylprednisolone)
Study: 1958279
Drug: CyA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyA plus MP (double drug combination)
Study: 1958279
Drug: Aza plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aza plus CyA (double drug combination)
Study: 1958279
Drug: Aza plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aza plus MP (double drug combination)
Study: 6184564
Drug: Captopril (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (1 mg/kg)
Study: 24321403
Drug: Text messages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text messages for medication reminders and education
Study: 20201481
Drug: New oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: New oral anticoagulants (direct thrombin inhibitors and direct factor Xa inhibitors)
Study: 20201481
Drug: Conventional anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional anticoagulants (warfarin and low-molecular-weight heparins)
Study: 10399110
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg orally once daily (n = 119)
Study: 10399110
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg orally twice daily (n = 117)
Study: 23239048
Drug: Synbiotic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic mixture (2.5 × 10(9) CFU live bacteria including Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium bifidum, Bifidobacterium longum, Enterococcus faecium, and 625 mg fructooligosaccharide) for 5 days
Study: 23239048
Drug: Control (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (conventional hydration therapy without synbiotic)
Study: 21215482
Drug: VIPER-BP intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIPER-BP intervention (intensive BP management strategy using valsartan-based therapy)
Study: 18061128
Drug: Longitudinal urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longitudinal urinary creatinine excretion data
Study: 12942142
Drug: Procyclidine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procyclidine (15 mg)
Study: 8441428
Drug: Low-dose unilateral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose unilateral electroconvulsive therapy
Study: 8441428
Drug: High-dose unilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose unilateral electroconvulsive therapy
Study: 8441428
Drug: Low-dose bilateral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose bilateral electroconvulsive therapy
Study: 8441428
Drug: High-dose bilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose bilateral electroconvulsive therapy
Study: 8441428
Drug: Bilateral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral therapy
Study: 8441428
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who responded to therapy
Study: 3954009
Drug: Reflective blanket
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reflective blanket and heated glycine 1.5% bladder irrigation solution